An AI-powered tool, RhinoMAP, personalizes treatments for asthma, COPD, and sinusitis using nasal liquid biopsy analysis. It provides drug recommendations within 48 hours, improving patient outcomes. Supported by $800K funding, it’s in clinical trials and could be widely available next year.